Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.
Cancer Network spoke with Ryan J. Sullivan, MD, medical oncologist at Massachusetts General Hospital, about why immunotherapy sequencing rather than immunotherapy targeted therapy should be the frontline treatment for melanoma.
